• Voyager Therapeutics (NASDAQ:VYGR) has selected a lead development candidate, VY1706, for its tau silencing gene therapy program in Alzheimer’s disease.
• Stock up 4% premarket.
• The company anticipates filing an investigational new drug application with the U.S. Food and Drug Administration and a clinical trial application with Health Canada for VY1706 in 2026.
• Source: Press Release

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。